COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy-Reference-Cited by-同舟云学术

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy

Published:2022-10 Issue:4 Volume:85 Page:436-480
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Coulson J.M.^ORCID,Adams A.,Gray L.A.,Evans A.^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference8 articles.

1. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19;Hammond;New Engl J Med,2022

2. K. Gupta, J. Strymish, G. Stack, M. Charness Rapid relapse of symptomatic omicron SARS CoV-2 infection following early suppression with nirmatrelvir/ritonavir. 26 April 2022, PREPRINT (Version 1) Accessed at Research Square doi:10.21203/rs.3.rs-1588371/v1.

3. M. Charness, K. Gupta, G. Stack, J. Strymish, E. Adams, D. Lindy, H. Mohi, D. Ho. Rapid relapse of symptomatic omicron SARS CoV-2 infection following early suppression with nirmatrelvir/ritonavir. 13 May 2022, PREPRINT (Version 2). Accessed at Research Square doi:10.21203/rs.3.rs-1588371/v2.

4. A.F. Carlin, A.E. Clark, A. Chaillon, A.F. Garretson, W. Bray, M. Porrachi, et al. Virologic and immunologic characterization of COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. 18 May 2022, PREPRINT (Version 1). Accessed at Research Square doi:10.21203/rs.3.rs-1662783/v1.

5. COVID-19 rebound after paxlovid treatment. CDCHAN-00467. 24th May 2022. Accessed on 26th May 2022 at https://emergency.cdc.gov/han/2022/han00467.asp.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19;BMC Infectious Diseases;2024-09-12

2. Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis;Tungs' Medical Journal;2024-08-08

3. Dynamic heterogeneity in COVID-19: Insights from a mathematical model;PLOS ONE;2024-05-31

4. Long COVID and its association with neurodegenerative diseases: pathogenesis, neuroimaging, and treatment;Frontiers in Neurology;2024-04-04

5. Natural products as a source of Coronavirus entry inhibitors;Frontiers in Cellular and Infection Microbiology;2024-02-21